

Erythropoietin Increases Expression and Function of Transient Receptor Potential Canonical 5 Channels

Ying Liu, Yunfei Xu, Florian Thilo, Ulla G. Friis, Boye L. Jensen, Alexandra Scholze, Junhua Zheng, Martin Tepel

Abstract—Hypertension is a common complication in hemodialysis patients during erythropoietin (EPO) treatment. The underlying mechanisms of EPO-induced hypertension still remain to be determined. Increased transient receptor potential canonical (TRPC) channels have been associated with hypertension. Now, TRPC gene expression was investigated using quantitative real-time RT-PCR and immunoblotting in cultured human endothelial cells and in monocytes from hemodialysis patients. EPO dose-dependently increased TRPC5 mRNA in endothelial cells. EPO increased TRPC5 mRNA stability, that is, EPO prolonged the half-life period for TRPC5 mRNA from 16 hours (control) to 24 hours ($P<0.05$). The poly(A) tail length was measured by rapid amplification of cDNA ends-poly(A) test. Increased TRPC5 mRNA stability was attributed to longer 3' poly(A) tail lengths after EPO administration. EPO also significantly increased TRPC5 channel protein abundance by 70% ($P<0.05$). Whole-cell patch clamp showed that angiotensin II-induced, TRPC5-mediated currents were dramatically increased in endothelial cells treated with EPO. Fluorescent dye techniques confirmed that increased calcium influx after EPO treatment was abolished after TRPC5 knockdown ($P<0.05$). EPO also significantly increased intracellular reactive oxygen species production. Knockdown of TRPC5 alleviated EPO-induced reactive oxygen species generation in endothelial cells ($P<0.05$). In vivo, EPO-treated hemodialysis patients showed significantly increased amounts of TRPC5 mRNA in monocytes compared with EPO-free hemodialysis patients (6.0 ± 2.4 [$n=12$] versus 1.0 ± 0.5 [$n=9$]; $P<0.01$). Patients undergoing EPO treatment also showed significantly elevated systolic blood pressure (160 ± 7 versus 139 ± 6 mm Hg; $P<0.05$). Our findings suggest that upregulated functional TRPC5 gene may be one cause of EPO-induced hypertension in patients with chronic kidney disease. (*Hypertension*. 2011;58:317-324.)

Key Words: transient receptor potential channel ■ erythropoietin ■ hypertension

Elevated arterial blood pressure is a common adverse effect of erythropoietin (EPO) administration in patients and animal models with chronic kidney disease.¹⁻⁴ Several observations indicate that EPO-induced hypertension is not only mediated by changes in erythrocyte mass but also by direct adverse effects of EPO. The underlying mechanisms of EPO-induced rise in blood pressure still remain to be determined.^{4,5} Considerable evidence has been accumulated for impaired cellular calcium homeostasis in EPO-associated hypertension. EPO significantly increases cytosolic free calcium concentration and expands sarcoplasmic calcium stores in platelets from essential hypertensive or EPO-associated hypertension patients and cultured vascular smooth muscle cells from rats.⁶⁻⁸

Transient receptor potential canonical (TRPC) channels are calcium-permeable nonselective cation channels that had been identified in many cell types, including endothelial cells and peripheral blood cells.⁹ We previously showed signifi-

cantly increased expression of functional TRPC5 channel protein in patients with essential hypertension and in spontaneously hypertensive rats.¹⁰⁻¹² In the present study, we hypothesized that EPO increases the expression and function of the TRPC5 gene, finally contributing to the pathogenesis of hypertension. To test this hypothesis, we examined the effects of EPO on TRPC5 channel expression and function in cultured human endothelial cells and peripheral blood cells.

Experimental Procedures

Cell Culture

Human umbilical vein endothelial cell-derived EA.hy926 cells (American Type Culture Collection) were maintained at 37°C and 5% CO₂ in DMEM containing 10% FCS, 100 U/mL of penicillin, and 100 µg/mL of streptomycin (BIOCHROM AG, Berlin, Germany). After detachment with 0.25% trypsin, cells were seeded in plates as appropriate, that is, 6-well plates for RNA and protein isolation, 12-well plates for patch clamp experiments, and 96-well

Received March 24, 2011; first decision April 21, 2011; revision accepted May 26, 2011.

From the Odense University Hospital (Y.L., U.G.F., B.L.J., A.S., M.T.), Department of Nephrology and Institute of Molecular Medicine, Odense, Denmark; Department of Urology (Y.L., Y.X., J.Z.), Tenth People's Hospital, Tongji University of Shanghai, People's Republic of China; Med Klinik Nephrologie (F.T.), Charité Campus Benjamin Franklin, Berlin, Germany.

Correspondence to Martin Tepel, Odense University Hospital and University of Southern Denmark, Institute for Molecular Medicine, Cardiovascular and Renal Research, Institute of Clinical Research, Winsløwparken 21.3, DK-5000 Odense C, Denmark. E-mail mtepel@health.sdu.dk

© 2011 American Heart Association, Inc.

Hypertension is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.111.173690

plates for intracellular calcium measurement. All of the experiments were performed using cells between passages 5 and 8. Cells were serum starved and incubated with different doses of EPO for 24 to 48 hours, as indicated.

Isolation of RNA and cDNA Synthesis

Total RNA was isolated from cells using the RNeasy minikit (Qiagen, Hilden, Germany). RNA was used to synthesize first-strand cDNA using the Transcriptor First Strand cDNA Synthesis kit (Roche Diagnostics, Mannheim, Germany). PCR was performed using a reverse transcription mixture consisting of 1 μ g of total RNA template, anchored-oligo(dT)₁₈ primer, and transcriptor reverse transcriptase and incubated according to the following procedure, denaturation at 65°C for 10 minutes, followed by 50°C for 60 minutes and heating at 85°C for 5 minutes.

Quantitative Real-Time RT-PCR

Quantitative real-time RT-PCR was performed as described by our group.¹³ The primers for coding regions of TRPC type 3 (TRPC3), type 5 (TRPC5), type 6 (TRPC6), or GAPDH were as follows: TRPC3 (NM_001130698.1) forward GCGCCGGAGGAGGAGGAAG and reverse AGGTCCGGCCCGTGGGAGAA; TRPC5 (NM_012471.2) forward CCACCAGCTATCAGATAAGG and reverse CGAAACAAGCCACTTATACC; TRPC6 (NM_004621.5) forward ACGACAGCAGACAATGGCGGTC and reverse CTTC-CCCATCTTGCTGCATGGAGC; and GAPDH (NM_002046.3) forward TGTTCGACAGTCAGCCGCATCTTC and reverse GGTGACCAGGCGCCCAATACG.

Quantitative real-time RT-PCR was performed using FastStart DNA Master SYBR Green I (Roche Diagnostics). PCR amplification conditions were 30 to 40 cycles of denaturation at 95°C for 10 seconds, annealing at 60°C for 10 seconds, and extension at 72°C for 15 seconds. After quantification, melting curves were generated with a heating rate of 0.1°C per second from 65° to 95°C. Data were recorded on a LightCycler 2.0 Instrument with LightCycler Software Version 4.0 (Roche Diagnostics). Normalized ratios of gene expressions were calculated as relative expressions of TRPCs normalized to the GAPDH gene, respectively.

PCR products were size fractionated on 1% agarose gels and were visualized by ethidium bromide staining using an imaging analyzer (GelDoc 2000; BioRad Laboratories, Munich, Germany). The expected product sizes were 164 (TRPC3), 159 (TRPC5), and 109 bp (TRPC6), respectively.

mRNA Decay Analysis

The effect of EPO on TRPC5 mRNA stability was examined by inhibiting mRNA transcription using actinomycin D (1 μ mol/L). After the cells had been incubated with EPO or vehicle in DMEM with 1% serum for 10 hours, actinomycin D was added, and the reduction of TRPC5 mRNA abundance was determined by quantitative real-time RT-PCR.

Rapid Amplification of cDNA Ends-Poly(A) Test

To measure the 3' poly(A) tail lengths of TRPC5 mRNA, rapid amplification of cDNA ends-poly(A) test was performed using a commercially available ALL-TAIL kit following the manufacturer's instructions (Bioo Scientific, Austin, TX). First, T4-RNA-ligase2 was used to join an adenylated adaptor oligonucleotide 5' rAppTT-TAACC GCGAATTCAG/3ddC/3' to the 3' end of total RNA. Next, reverse transcription was performed using a primer specific to the adenylated adaptor to initiate the production of cDNA. The primers used for amplification of the poly(A) tail and a short stretch of the 3' untranslated region of TRPC5 transcripts were forward AGAACCTGGGCTACATTCCT and reverse CTGGAATTCGCG-GTTAAA. PCR products were separated on 1.8% agarose gels and were visualized by ethidium bromide.

Knockdown of TRPC5 by Small Interfering RNA

Endothelial cells were transfected with small interfering RNA (siRNA) specific for TRPC5 for 48 hours using a silencer siRNA transfection kit (Ambion, Cambridgeshire, United Kingdom). Briefly, endothelial cells in DMEM containing 10% FBS were incubated with siPORT amine (Ambion) and chemically synthesized siRNA (10 nmol/L; Ambion) specific for TRPC5. The target sequence for TRPC5 was 5'-GGAGGCUGAGAUCUACUAUtt-3' (sense) and 5'-AUAGUAGAUCU CAGCCUCctg-3' (antisense). In control experiments, negative control siRNA (Ambion) that has no significant homology to any known human gene sequence did not affect TRPC expression.

Immunoblotting of TRPC5

Immunoblotting was performed as described by our group.^{10,13} Cells were washed with ice-cold PBS and were collected in 500 μ L of ice-cold lysis buffer containing Tris-HCl (25 mmol/L; pH 8.0), NaCl (150 mmol/L), EDTA (1 mmol/L), 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate (20 mmol/L), phenylmethane sulfonyl fluoride (1 mmol/L), and complete mini protease inhibitor mixture (Roche Diagnostics). Proteins were separated by 10% SDS-PAGE at 100 V for 30 minutes followed by 150 V for 60 minutes and transferred to Hybond-ECL nitrocellulose membranes (NEN Life Science, Boston, MA). Membranes were blocked with Odyssey blocking buffer (Licor Biosciences, Bad Homburg, Germany) overnight at 4°C. Membranes were incubated with primary antibodies, that is, rabbit anti-TRPC5 antibody (1:500, Alomone Labs, Jerusalem, Israel) together with goat anti-rat GAPDH antibodies (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. The membranes were washed 3 times with PBS containing 0.1% Tween 20 and were subsequently incubated with secondary IRDye800CW-infrared fluorescent dye-labeled sheep anti-rabbit antibodies (1:1000, Biomol, Hamburg, Germany) and Alexa Fluor680-allophycocyanin-fluorescence-labeled donkey anti-goat antibodies (1:1000; Invitrogen, Eugene, OR) for 60 minutes at room temperature with gentle agitation. After washing, imaging was performed using the Odyssey infrared imaging system (Licor Biosciences) at 810 nm emission with an excitation wavelength of 780 nm and at 700 nm emission with an excitation wavelength of 680 nm. The predicted molecular weights are 97 kDa for TRPC5 and 37 kDa for GAPDH, respectively.

Quantitative In-Cell Western Assay of TRPC5

Quantitative in-cell Western assays of proteins were performed using the Odyssey infrared imaging system (Licor biosciences), as described by our group.^{10,11} Cells were grown on 96-well plates and fixed by 3.7% formaldehyde. Measurements were performed in quadruplicate and averaged.

Intracellular Calcium Measurements Using Fluorescence Spectrophotometry

Endothelial cells were seeded onto 96-well plates and incubated with the calcium indicator fluo-4AM (5 μ mol/L) for 60 minutes at room temperature. Cells were then washed with physiological saline solution containing 134 mmol/L of NaCl, 6 mmol/L of KCl, 2 mmol/L of CaCl₂, 1 mmol/L of MgCl₂, 10 mmol/L of glucose, and 10 mmol/L of HEPES (pH 7.4 with NaOH) to remove extraneous dye. Fluorescence was measured using a fluorescent plate reader (Victor3, Helsinki, Finland) at 535 nm emission with excitation wavelength of 485 nm. TRPC was activated by angiotensin II (Ang II). The amplitudes were expressed as fractional fluorescence increase (F/F₀).

Patch Clamp Experiments

Membrane currents were recorded using the whole-cell configuration of the patch clamp technique as described by our group.¹⁴ Experiments were performed at room temperature in the tight-seal whole-cell configuration of the patch-clamp technique with heat-polished,

patch pipettes with resistances of 4 to 6 mol/L Ω . Series resistances were in the range of 10 to 35 mol/L Ω , and seal resistances were in the range of 1 to 2 G Ω . High-resolution membrane currents were recorded with an EPC-9 patch-clamp amplifier (HEKA) controlled by PULSE software on a Power Macintosh computer (G3). High-resolution currents were low-pass filtered at 2.9 kHz. The reference electrode was an Ag/AgCl pellet connected to the bath solution through a 150-mmol/L NaCl/agar bridge. Whole cell currents were elicited by voltage ramps from -120 to $+120$ mV (300-ms duration) applied every 15 seconds from a holding potential of -40 mV. Pipettes for whole cell recordings were filled with a solution composed of 130 mmol/L of CsCH₃O₃S, 10 mmol/L of CsCl, 2 mmol/L of MgCl₂, and 10 mmol/L of HEPES (pH 7.2 with CsOH). The standard bath solution contained 140 mmol/L of NaCl, 2.8 mmol/L of KCl, 2 mmol/L of CaCl₂, 1 mmol/L of MgCl₂, 11 mmol/L of glucose, 10 mmol/L of sucrose, and 10 mmol/L of HEPES (pH 7.4 with NaOH). Ang II (200 nmol/L) was added to the cell via an application pipette positioned in close proximity to the cell.

Assessment of Intracellular Reactive Oxygen Species

Intracellular reactive oxygen species (ROS) generation was assessed in endothelial cells using 5-(6-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (CM-H₂DCFDA), a cell-permeable indicator for ROS. In brief, endothelial cells were seeded equally in a 96-well plate and treated with 10 μ mol/L of CM-H₂DCFDA (Invitrogen, Eugene, OR) for 40 minutes at 37°C in the dark. For cells washing and loading, the following physiological saline solution was used: 134 mmol/L of NaCl, 6 mmol/L of KCl, 2 mmol/L of CaCl₂, 1 mmol/L of MgCl₂, 10 mmol/L of glucose, and 10 mmol/L of HEPES (pH 7.4 with NaOH). Mean fluorescence intensity was measured using a fluorescent plate reader (Victor3) at 535 nm emission with excitation wavelength of 485 nm. Untreated cells were used to determine background fluorescence, which was subtracted from the treated samples.

Patients

A total of 21 hemodialysis patients (17 men and 4 women; mean age: 63 ± 2 years; dialysis vintage: 44 ± 12 months) were investigated. Patient history was raised using a standardized questionnaire and was composed of personal histories, smoking habits, cause of kidney disease, months of hemodialysis treatment, preexisting cardiovascular disease (ie, history of myocardial infarction, need for coronary angioplasty or coronary bypass surgery, ischemic stroke, or peripheral vascular disease with the need for amputation or angioplasty), presence of diabetes mellitus, and current medication, including angiotensin-converting enzyme inhibitors, β -blockers, lipid-lowering agents, or EPO. Blood pressure was measured predialysis after a rest period of 10 minutes of recumbency. The study was approved by the local ethics committee. All of the patients gave written, informed consent. The cause of end-stage renal disease was diabetic nephropathy in 6 cases (28%), nephrosclerosis in 5 cases (24%), chronic glomerulonephritis in 2 cases (10%), polycystic kidney disease in 1 case (5%), and other/unknown in 7 cases (33%). Angiotensin-converting enzyme inhibitors were prescribed in 2 cases (10%), β -blockers in 13 cases (62%), calcium channel blockers in 3 cases (14%), and EPO therapy in 12 cases (57%). Mean duration of hemodialysis at inclusion was 44 ± 12 months. All of the patients were routinely dialyzed for 4 to 5 hours 3 times weekly using biocompatible membranes with no dialyzer reuse. The dialysates used were bicarbonate based. All of the patients were ambulatory and free of acute intercurrent illness. Mean leukocyte count was $9.3 \pm 0.6 \times 10^9/L$, mean hemoglobin level 9.9 ± 0.3 mg/dL, mean platelet count $253 \pm 27 \times 10^9/L$, serum creatinine 6.5 ± 0.6 mg/dL, blood urea 85 ± 10 mg/dL, serum albumin 3.3 ± 0.2 g/L, serum calcium 2.24 ± 0.05 mmol/L, and serum phosphate 1.71 ± 0.16 mmol/L. Mean dose of dialysis (kt/V) was 1.2 ± 0.1 .

Preparation of Monocytes

Human monocytes were prepared using antibody coated superparamagnetic polystyrene beads coated with a primary monoclonal antibody specific for the CD14 membrane antigen expressed on human monocytes (DynaL Biotech, Hamburg, Germany). Briefly, mononuclear cells were obtained from heparinized blood using HISTOPAQUE-1077 and purified by superparamagnetic polystyrene beads. Cells were then resuspended in Hanks' balanced salt solution containing the following: NaCl, 136 mmol/L; KCl, 5.40 mmol/L; KH₂PO₄, 0.44 mmol/L; Na₂HPO₄, 0.34 mmol/L; D-glucose, 5.6 mmol/L; CaCl₂, 1 mmol/L; and HEPES, 10 mmol/L (pH 7.4).

Materials

Ang II, phosphoinositide 3-kinase (PI3K) inhibitor LY294002, Rho-associated protein kinase inhibitor Y27632, and mitogen-activated protein kinase kinase inhibitor PD98059 were purchased from Sigma-Aldrich (Deisenhofen, Germany). EPO (epoetin- β) was purchased from Roche (Mannheim, Germany).

Statistical Analysis

All of the data were expressed as the mean \pm SEM. Comparisons between groups were analyzed using the Mann-Whitney test or ANOVA and Bonferroni multiple comparison test as appropriate. A 2-tailed *P* value <0.05 was considered statistically significant.

Results

Dose-Dependent Effect of EPO on TRPC mRNA Levels

Using quantitative real-time RT-PCR, we detected TRPC3, TRPC5, and TRPC6 mRNA in cultured endothelial cells. PCR products appeared at expected molecular weight on the agarose gel. Melting analysis confirmed the presence of a single peak for all 3 of the TRPC channel members (Figure 1A and 1B). Incubation of endothelial cells with EPO for 24 hours resulted in a dose-dependent upregulation of TRPC5 mRNA (Figure 1C). EPO at 100 U/mL significantly increased TRPC5 mRNA by 79%.

Effect of EPO on TRPC5 mRNA Stability

The increased TRPC5 mRNA could be because of increased mRNA stability. To address this question, we examined EPO mRNA stability by inhibiting new mRNA transcription with actinomycin D. After the cells had been incubated with EPO, actinomycin D (1 μ mol/L) was added, and the time-dependent decay of TRPC5 mRNA was measured by real-time RT-PCR. EPO increased TRPC5 mRNA stability in endothelial cells, that is, EPO prolonged the half-life period for TRPC5 mRNA from 16 hours under control conditions to 24 hours after EPO treatment (each $n=3$; $P<0.05$; Figure 1D).

Identification of TRPC5 mRNA With Long Poly(A) Tails With Rapid Amplification of cDNA Ends-Poly(A) Test

The 3' poly(A) tail plays an important role in determining mRNA stability. Longer 3' poly(A) tail length causes increased mRNA stability because of reduced degradation. Thus, we examined the 3' poly(A) tail lengths of the TRPC5 mRNA in endothelial cells treated with or without EPO. As shown in Figure 1E, EPO increased 3' poly(A) tail lengths of TRPC5 mRNA, as indicated by separating PCR products on




Figure 1. Erythropoietin (EPO) upregulates transient receptor potential canonical (TRPC) 5 mRNA but not TRPC3 nor TRPC6 in endothelial cells. **A**, Gel electrophoresis of PCR products from mRNA of TRPC3, TRPC5, and TRPC6. –RT indicates RNA without reverse transcriptase; –RNA, no RNA with reverse transcriptase. Marker denotes 100-bp ladder. **B**, Melting analysis after amplification of TRPC3, TRPC5, and TRPC6. Melting curve and melting peak are shown. **C**, Dose-dependent upregulation of TRPC5 mRNA by EPO. Bar graph gives the normalized ratio of TRPC expression vs GAPDH expression (each $n=3$). **D**, TRPC5 mRNA stability was estimated by inhibition of gene transcription with actinomycin D ($1 \mu\text{mol/L}$). Data are means of 3 separate experiments. Lines were significantly different (ANOVA and posttest for linear trend, $P<0.01$). **E**, Rapid amplification of cDNA ends-poly(A) test (RACE-PAT) results. Ethidium bromide staining of PCR products separated on 1.8% agarose gels showing increased length of poly(A) tail of TRPC5 mRNA in EPO-treated samples. Bar graph summarizing densitometric data expressing the ratio of long poly(A) TRPC5 (≈ 200 -bp bands) to short poly(A) TRPC5 (≈ 150 -bp bands) ($n=4$).

agarose gels. In endothelial cells exposed to EPO for 48 hours, there was a significant increase in the ratio of long (≈ 200 -bp bands) to short (≈ 150 -bp bands) poly(A) of TRPC5 fragments (2.8 ± 0.4 versus 1.0 ± 0.1 ; each $n=4$; $P<0.05$).

Effect of EPO on TRPC5 Protein Expression

To confirm that the increased TRPC5 mRNA abundance facilitated gene translation, we investigated TRPC5 protein abundance using both immunoblotting and quantitative in cell Western techniques. In accordance with transcripts data, TRPC5 protein expression was also significantly higher in endothelial cells after incubation with EPO (100 U/mL) for 48 hours compared with control (1.0 ± 0.1 versus 1.7 ± 0.1 ; each $n=4$; $P<0.05$; Figure 2).

Effect of EPO on TRPC5-Mediated Currents and Calcium Influx

Patch clamp studies indicated that Ang II (200 nmol/L) could induce TRPC-like channel-mediated currents in endothelial cells (Figure 3A). Cells pretreated with EPO for 48 hours exhibited a pronounced increase in such currents, whereas cell capacitance was unchanged. Furthermore, Ang II-induced calcium influx was significantly increased in EPO-treated endothelial cells compared with control conditions (EPO 1.1 ± 0.1 versus control 0.5 ± 0.1 ; each $n=5$; $P<0.05$).

After TRPC5 knockdown, the increased calcium influx after EPO treatment was abolished (siRNA against TRPC5 plus EPO, 0.6 ± 0.1 ; each $n=5$; $P<0.05$ compared with EPO alone; Figure 3B and 3C).

Inhibition of PI3K Attenuates the EPO-Enhanced Ang II-Induced Calcium Influx

As shown in Figure 3D, the enhanced Ang II-induced calcium influx after EPO was blocked in the presence of the PI3K inhibitor LY294002. On the other hand, Rho-associated protein kinase inhibitor Y27632 and mitogen-activated protein kinase kinase inhibitor PD98059 did not affect the Ang II-induced calcium influx after EPO.

Effect of EPO on Intracellular ROS Generation in Endothelial Cells

As shown in Figure 3E, incubation of EPO in endothelial cells for 48 hours significantly increased ROS generation by 70% compared with the control (EPO: 1.7 ± 0.1 ; control: 1.0 ± 0.1 ; each $n=4$; $P<0.05$). After TRPC5 knockdown, the EPO-induced intracellular ROS production was not significantly different compared with control conditions (each $n=4$; $P>0.05$). There was no significant difference between the EPO-free control and EPO-free control treated with negative control siRNA, which has no significant homology to any known human gene sequence.




Figure 2. Erythropoietin (EPO) upregulates transient receptor potential canonical (TRPC) 5 channel proteins. **A**, Immunoblotting of TRPC5 and GAPDH in endothelial cells treated with vehicle (control) or with EPO. **B**, Representative immunofluorescence assay (top) and summary data (bar graph) showing the expression of TRPC5 channel proteins normalized to GAPDH proteins. Blank indicates omitting primary antibodies. For the representative immunofluorescence experiment, measurements were performed in quadruplicate. This experiment was repeated 2 times. * $P<0.05$ vs control.

Effect of Long-Term EPO Treatment on TRPC5 mRNA Levels and Blood Pressure in Hemodialysis Patients

EPO-treated hemodialysis patients showed significantly increased amounts of TRPC5 mRNA in monocytes compared with EPO-free hemodialysis patients (EPO-treated, 6.0 ± 2.4 [n=12] versus EPO-free, 1.0 ± 0.5 [n=9]; $P<0.05$; Figure 4A). Patients undergoing EPO treatment also showed significantly elevated systolic blood pressure (EPO-treated, 160 ± 7 mm Hg [n=12] versus EPO-free, 139 ± 6 mm Hg [n=9]; $P<0.05$; Figure 4B). On the other hand, clinical and biochemical data were not significantly different between EPO-treated and EPO-free hemodialysis patients (age: 62 ± 4 years [n=12] versus 65 ± 4 years [n=9]; dialysis vintage: 49 ± 18 months versus 31 ± 12 months; leukocytes: $9.7 \pm 0.8 \times 10^9/L$ versus $8.9 \pm 0.9 \times 10^9/L$; hemoglobin: 9.7 ± 0.5 g/dL versus 10.3 ± 0.5 g/dL; platelets: $244 \pm 37 \times 10^9/L$ versus $265 \pm 39 \times 10^9/L$; serum creatinine: 6.6 ± 0.8 mg/dL versus 6.4 ± 1.1 mg/dL; blood urea: 76 ± 15 mg/dL versus 102 ± 14 mg/dL; serum albumin: 3.1 ± 0.2 mg/dL versus 3.3 ± 0.3 mg/dL; serum calcium: 2.26 ± 0.07 mmol/L versus

2.22 ± 0.07 mmol/L; serum phosphate: 1.65 ± 0.20 mmol/L versus 1.81 ± 0.30 mmol/L; each $P>0.05$ between the groups).

Discussion

In the present study we showed that EPO increases TRPC5 gene expression and function. Treatment with EPO resulted in a dose-dependent increase in TRPC5 mRNA by enhancing TRPC5 mRNA stability via increased 3' polyadenylation. Consequentially, upregulated TRPC5 protein abundance was accompanied by increased currents, calcium influx, and enhanced oxidative stress in endothelial cells.

EPO is a well-known growth factor causing maturation of erythroblasts. EPO receptors have been identified in several cell types, including endothelial cells.^{15,16} In the literature there are several examples showing that EPO can increase gene expression in several tissues.^{17–19} d'Uscio et al¹⁷ showed that EPO increased the expression of copper- and zinc-containing superoxide dismutase in vascular tissue. Grossi et al¹⁸ showed that EPO upregulates the expression of the EPO receptor in a TF-1 cell line. As reported by Acquaviva et al,¹⁹ EPO administration enhanced frataxin protein in primary fibroblasts.

Results from RT-PCR using subtype-specific primers indicate that TRPC3, TRPC5, and TRPC6 were expressed in endothelial cells. Our results showed that EPO selectively increases TRPC5 but not TRPC3 or TRPC6 mRNA in a dose-dependent manner. The specific EPO-TRPC5 interaction underscores TRPC subtype-specific characteristics of TRPC5 compared with TRPC3 and TRPC6. Based on their different structure, TRPC5 belongs to the TRPC4/5 subfamily, whereas TRPC3 and TRPC6 belong to TRPC3/6/7 subfamily.⁹ Furthermore, these TRPC channels show different electrophysiological characteristics. TRPC5 channels can be activated by lanthanum (La^{3+}) and do not respond to diacylglycerol. By contrast, TRPC3 and TRPC6 channels are inhibited by micromolar concentrations of La^{3+} and can be activated by diacylglycerol.^{9,20} We showed that EPO increases TRPC5 mRNA by enhancing its stability. A long 3' poly(A) tail is important for mRNA stabilization. A long 3' poly(A) tail facilitates binding of multiple poly(A) binding protein molecules, which protects against ribonucleolytic attack and allows mRNA-ribosome interactions.^{21,22} Using the rapid amplification of cDNA ends-poly(A) test we observed that EPO increased TRPC5 mRNA with long 3' poly(A) tails. These findings shed light on a novel mechanism by which EPO affects gene transcription. We also showed that increased TRPC5 mRNA caused increased TRPC5 protein abundance. Taken together, we provide direct evidence that EPO upregulates TRPC5 gene expression at both transcriptional and translational levels, likely because of increased polyadenylation in the 3' poly(A) tail of TRPC5 mRNA.

We further investigated the functional consequences of increased expression of the TRPC5 gene. Our in vitro studies indicated that the administration of EPO increased TRPC5-mediated currents and calcium influx in endothelial cells. Altered TRPC channel function may contribute to hypertension. TRPC5 channels are nonselective cationic channels that




Figure 3. Erythropoietin (EPO) affects transient receptor potential canonical (TRPC) 5-associated calcium influx and reactive oxygen species (ROS) generation in cultured endothelial cells. **A**, TRPC-like currents in endothelial cells pretreated with vehicle (control) or EPO. To exclude potassium channel currents, pipettes for whole cell recordings were filled with solution containing cesium. **B**, Immunoblots confirming knockdown of TRPC5 channel proteins using gene silence techniques. Control indicates negative control small interfering RNA (siRNA) that has no significant homology to any known human gene sequence. **C**, Representative recordings and summary data (bar graph) of Ang II-induced calcium influx. siRNA+EPO indicates siRNA against TRPC5 plus EPO; control indicates negative control siRNA that has no significant homology to any known human gene sequence. * $P<0.05$. **D**, Inhibition of the phosphoinositide 3-kinase (PI3K) using LY294002 attenuated calcium influx in EPO-treated cells. $n=5$ in each group. * $P<0.05$. **E**, Measurement of intracellular ROS generation in cultured endothelial cells. Cells were subject to EPO treatment for 48 hours. Cells were then loaded with the intracellular fluoroprobe CM-H₂DCFDA (10 μ mol/L), and fluorescence intensity was measured. Intracellular ROS formation was expressed as the mean fluorescence intensity and normalized to control. Experiments were performed in quadruplicate. * $P<0.05$.

can be activated by G protein-coupled receptors.²³ Several reports showed an increased agonist-induced calcium influx in hypertension.^{10–12} In line with previous reports, we show that Ang II induced a strong increase of calcium influx through TRPC-like channels in endothelial cells. Furthermore, Ang II-induced calcium influx was significantly attenuated after specific TRPC5 knockdown using gene silence techniques. The TRPC5-mediated calcium influx underlies a key signaling mechanism that stimulates the calcium-dependent release of several endothelium-derived vasoconstrictive agents, including endothelin, urotensin, or epoxyeicosatrienoic acids, which contributes to the development of hypertension.^{24–26} A recent study also showed that TRPC5 is

activated by pressure-induced membrane stretch associated with hypertension.²⁷

EPO has been shown to initiate a cascade of downstream signaling pathways, for example, PI3K, Rho-associated protein kinase, and mitogen-activated protein kinase, to affect endothelial cell function.^{28–31} Our data showed that the enhanced Ang II-induced calcium influx in EPO-treated cells could be blocked by the PI3K inhibitor LY294002 but not by Rho-associated protein kinase inhibitor Y27632 or mitogen-activated protein kinase inhibitor PD98059. These data are consistent with previous reports showing growth factors induced incorporation of functional TRPC5 channels in a PI3K-dependent manner.³²




Figure 4. In vivo effect of erythropoietin (EPO). **A**, Patients with end-stage renal disease receiving EPO therapy showed increased transient receptor potential canonical (TRPC) 5 mRNA expression (EPO-treated, 6.0 ± 2.4 [$n=12$] vs EPO-free, 1.0 ± 0.5 [$n=9$]; $*P < 0.05$). **B**, Patients receiving EPO treatment showed elevated blood pressure (EPO-treated, 160 ± 7 mm Hg [$n=12$] vs EPO-free, 139 ± 6 mm Hg [$n=9$]; $*P < 0.05$).

Using the fluorescent dye techniques, we observed that endothelial cells incubated with exogenous EPO showed enhanced oxidative stress, as indicated by increased intracellular ROS production. These findings are supported by several studies, showing that EPO generates significant oxidative stress and oxidant damage both in vivo and in vitro.^{33–35} We have further shown that knockdown of TRPC5 is accompanied by reduced intracellular ROS production, which was induced by EPO in endothelial cells. Recently, it was reported that agonist-stimulated cytosolic calcium increase is followed by an increase in ROS formation in endothelial cells.³⁶ Because TRPC5 channels are calcium permeable, elevated agonist-stimulated calcium influx through upregulated TRPC5 channels in endothelial cells during EPO treatment may contribute to the ROS formation, which underlies pathogenesis of EPO-induced hypertension.

The present results may put light on the mechanisms underlying development of hypertension during EPO treatment in hemodialysis patients. Large clinical studies uncovered that elevated blood pressure is a frequent adverse effect of EPO treatment.^{1–3} In line with these findings we gave evidence that hemodialysis patients treated with EPO had higher systolic blood pressure. Furthermore, these patients had significantly increased expression of TRPC5 compared with EPO-free hemodialysis patients. These in vivo findings support our in vitro results, showing that EPO treatment upregulates TRPC5 expression. Together, TRPC5 may act as an essential downstream effector molecule for EPO signaling and may contribute to the hypertensive adverse effects observed during EPO therapy. In the present study we investigated TRPC5 expression in peripheral blood cells from hemodialysis patients without and with EPO administration. However, it is not presently known whether similar effects of EPO on TRPC5 expression can also be observed in the patient vasculature.

In conclusion, we demonstrate that EPO stabilizes TRPC5 mRNA, increases TRPC5 protein expression, and augments TRPC5-mediated currents and calcium influx in endothelial cells. EPO-induced oxidative stress can also be attenuated by knockdown of TRPC5. Finally, an increased TRPC5 mRNA is associated with elevated blood pressure in hemodialysis patients during EPO therapy.

Perspectives

The goal of EPO treatment is to increase hematocrit and hemoglobin in dialysis patients. However, hypertension is frequently observed during such treatment. The extent of the rise in blood pressure has been shown to correlate with increased hematocrit, as well as increased risk of mortality and cardiovascular events. Thus, the definite mechanisms of EPO-associated hypertension need to be determined.

TRPC channels are calcium-permeable nonselective cation channels that had been identified in endothelial cells and peripheral blood cells. Many investigators have shown that significantly increased TRPC channel protein is associated with hypertensive events in both human and animal models. The present study unveils a novel mechanism by which EPO affects TRPC gene transcription. EPO administration facilitates the translation of TRPC5 gene by prolonging the 3' poly(A) tail of TRPC5 transcripts. Furthermore, these TRPC5 channel proteins are functional, as confirmed by TRPC5-mediated increased currents, increased calcium influx, and enhanced oxidative stress in endothelial cells. EPO-induced above effects can be eliminated by knockdown of TRPC5 using gene silence techniques. Our in vitro findings are also supported by our in vivo data, showing that hemodialysis patients treated with EPO had higher systolic blood pressure and significantly increased expression of TRPC5 compared with EPO-free hemodialysis patients. We, therefore, speculate that upregulated TRPC5 might have functional relevance in the pathogenesis of EPO-associated hypertension in patients with chronic kidney disease. The TRPC5-mediated calcium influx underlies a key signaling event that stimulates not only the calcium-dependent release of several endothelium-derived vasoconstrictive agents, for example, endothelin, urotensin, or epoxyeicosatrienoic acids, but also calcium-dependent generation of ROS. These mediators can contribute to the development of hypertension.

Future studies should examine the effects of EPO, for example, on the intact endothelium in humans. Presently there is no drug available for humans that specifically blocks TRPC5 channels. When novel drugs blocking TRPC5 activity are available, they should be tested in a model of EPO-induced hypertension for further validation of the observed mechanisms.

Sources of Funding

This study was supported by Else-Kröner-Fresenius Stiftung.

Disclosures

None.

References

1. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, for the CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med*. 2006;355:2071–2084.
2. Singh AK, Szczec L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, for the CHOIR Investigators. Correction of anemia with epoetin α in chronic kidney disease. *N Engl J Med*. 2006;355:2085–2098.
3. Pfeffer MA, Burdman EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, for the TREAT Investigators. A trial of darbepoetin

- alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med*. 2009;361:2019–2032.
4. Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE. In vivo and in vitro pressor effects of erythropoietin in rats. *Am J Physiol*. 1995;269:F838–F845.
 5. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. *Clin J Am Soc Nephrol*. 2007;2:1274–1282.
 6. Tepel M, Wischniowski H, Zidek W. Erythropoietin induced transmembrane calcium influx in essential hypertension. *Life Sci*. 1992;51:161–167.
 7. Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. *Cardiovasc Res*. 1993;27:1233–1236.
 8. Schiffli H, Lang SM. Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin: pathogenetic role of cytosolic calcium. *Eur J Med Res*. 1997;2:97–100.
 9. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. *Physiol Rev*. 2007;87:165–217.
 10. Liu D, Scholze A, Zhu Z, Krueger K, Thilo F, Burkert A, Streffer K, Holz S, Harteneck C, Zidek W, Tepel M. Transient receptor potential channels in essential hypertension. *J Hypertens*. 2006;24:1105–1114.
 11. Liu DY, Thilo F, Scholze A, Wittstock A, Zhao ZG, Harteneck C, Zidek W, Zhu ZM, Tepel M. Increased store-operated and 1-oleoyl-2-acetyl-sn-glycerol-induced calcium influx in monocytes is mediated by transient receptor potential canonical channels in human essential hypertension. *J Hypertens*. 2007;25:799–808.
 12. Chen X, Yang D, Ma S, He H, Luo Z, Feng X, Cao T, Ma L, Yan Z, Liu D, Tepel M, Zhu Z. Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels. *J Cell Mol Med*. 2010;14:2483–2494.
 13. Liu Y, Thilo F, Kreutz R, Schulz A, Wendt N, Lodenkemper C, Jankowski V, Tepel M. Tissue expression of TRPC3 and TRPC6 in hypertensive Munich Wistar Frömter rats showing proteinuria. *Am J Nephrol*. 2010;31:36–44.
 14. Friis UG, Madsen K, Svenningsen P, Hansen PB, Gulaveerasingam A, Jørgensen F, Aalkjaer C, Skøtt O, Jensen BL. Hypotonicity-induced renin exocytosis from juxtaglomerular cells requires aquaporin-1 and cyclooxygenase-2. *J Am Soc Nephrol*. 2009;20:2154–2161.
 15. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. *Oncologist*. 2004;9(suppl 5):18–30.
 16. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. *Blood*. 1999;93:2627–2636.
 17. d'Uscio LV, Smith LA, Katusic ZS. Erythropoietin increases expression and function of vascular copper- and zinc-containing superoxide dismutase. *Hypertension*. 2010;55:998–1004.
 18. Grossi A, Vannucchi AM, Bacci P, Caporale R, Cappelli G, Visconti G, Pagliai G, Ferrini PR. Erythropoietin upregulates the expression of its own receptor in TF-1 cell line. *Leuk Res*. 1998;22:145–151.
 19. Acquaviva F, Castaldo I, Filla A, Giacchetti M, Marmolino D, Monticelli A, Pinelli M, Saccà F, Cocozza S. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. *Cerebellum*. 2008;7:360–365.
 20. Jung S, Mühle A, Schaefer M, Strotmann R, Schultz G, Plant TD. Lanthanides potentiate TRPC5 currents by an action at extracellular sites close to the pore mouth. *J Biol Chem*. 2003;278:3562–3571.
 21. Wang Z, Day N, Trifillis P, Kiledjian M. An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro. *Mol Cell Biol*. 1999;19:4552–4560.
 22. Mazumder B, Seshadri V, Fox PL. Translational control by the 3'-UTR: the ends specify the means. *Trends Biochem Sci*. 2003;28:91–98.
 23. Tian D, Jacobo SM, Billing D, Rozkalne A, Gage SD, Anagnostou T, Pavenstädt H, Hsu HH, Schlondorff J, Ramos A, Greka A. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. *Sci Signal*. 2010;3:ra77.
 24. Fleming I, Busse R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. *Hypertension*. 2006;47:629–633.
 25. Watanabe T, Kanome T, Miyazaki A, Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. *Hypertens Res*. 2006;29:375–387.
 26. Thijssen DH, Rongen GA, Smits P, Hopman MT. Physical (in)activity and endothelium-derived constricting factors: overlooked adaptations. *J Physiol*. 2008;586:319–324.
 27. Gomis A, Soriano S, Belmonte C, Viana F. Hypoosmotic- and pressure-induced membrane stretch activate TRPC5 channels. *J Physiol*. 2008;586:5633–5649.
 28. Chen C, Sytkowski AJ. Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc. *J Biol Chem*. 2001;276:38518–38526.
 29. Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14–3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. *Br J Pharmacol*. 2007;150:839–850.
 30. Hamadmad SN, Hohl RJ. Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. *J Pharmacol Exp Ther*. 2008;324:1227–1233.
 31. Ito C, Kusano E, Furukawa Y, Yamamoto H, Takeda S, Akimoto T, Iimura O, Ando Y, Asano Y. Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells. *Am J Physiol Cell Physiol*. 2002;283:C1715–C1721.
 32. Bezzerides VJ, Ramsey IS, Kotecha S, Greka A, Clapham DE. Rapid vesicular translocation and insertion of TRP channels. *Nat Cell Biol*. 2004;6:709–720.
 33. Herrera J, Nava M, Romero F, Rodríguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. *Am J Kidney Dis*. 2001;37:750–757.
 34. Chen HC, Tsai JC, Tsai JH, Lai YH. Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorphonuclear leukocytes in hemodialysis patients. *Kidney Int*. 1997;52:1390–1394.
 35. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Täger M, Bode-Böger SM. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. *J Am Soc Nephrol*. 2005;16:892–898.
 36. Wilkinson JA, Jacob R. Agonist-induced calcium and oxidative stress responses in endothelial cells. *Biochem Soc Trans*. 2003;31:960–962.

Erythropoietin Increases Expression and Function of Transient Receptor Potential Canonical 5 Channels

Ying Liu, Yunfei Xu, Florian Thilo, Ulla G. Friis, Boye L. Jensen, Alexandra Scholze, Junhua Zheng and Martin Tepel

Hypertension. 2011;58:317-324; originally published online June 20, 2011;
doi: 10.1161/HYPERTENSIONAHA.111.173690

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:

<http://hyper.ahajournals.org/content/58/2/317>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Hypertension* is online at:
<http://hyper.ahajournals.org/subscriptions/>